Welcome to the international HTA database

Showing [23806 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Esketamine (depression) - Benefit assessment according to §35a Social Code Book V]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Tafamidis for transthyretin amyloid cardiomyopathy]
2021	National Institute for Health and Care Excellence (NICE)	Bimekizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 723
2021	Center for Drug Evaluation (CDE)	[Review of international guidelines and comparative effectiveness of high cost antidiabetes drugs]
2021	European Network for Health Technology Assessment (EUnetHTA)	Ivermectin for the treatment of COVID-19
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: hospital at home, an alternative to conventional hospitalization]
2021	Institute of Health Economics (IHE)	Optimizing vascular risk reduction initiatives in Alberta: a clinical review and economic analysis
2021	Institute for Clinical and Economic Review (ICER)	JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Esketamine (depression, acute treatment) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer. NICE technology appraisal guidance 724
2021	Center for Drug Evaluation (CDE)	[Descriptive study and comparative effectiveness of listed medications for osteoporosis on new osteoporotic fracture event in osteoporosis patients by using National Health Insurance claim database]
2021	European Network for Health Technology Assessment (EUnetHTA)	Aspirin for the treatment of COVID-19
2021	NIHR Health Technology Assessment programme	Non-invasive imaging software to assess the functional significance of coronary stenoses: a systematic review and economic evaluation
2021	Institute for Clinical and Economic Review (ICER)	Aducanumab for Alzheimer's disease: effectiveness and value
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[High-flow therapy for self-use in advanced COPD or chronic type 1 respiratory failure]
2021	National Institute for Health and Care Excellence (NICE)	Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 725
2021	Center for Drug Evaluation (CDE)	[A systematic review of the comparative efficacy and cost-effectiveness of current listed statins in Taiwan]
2021	NIHR Health Technology Assessment programme	The ACUTE (Ambulance CPAP: Use, Treatment effect and Economics) feasibility study: a pilot randomised controlled trial of prehospital CPAP for acute respiratory failure
2021	Swiss Federal Office of Public Health (FOPH)	Corneal collagen crosslinking for the treatment of progressive keratoconus
2021	Institute for Clinical and Economic Review (ICER)	Anti b-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Decision aid knee endoprosthesis]
2021	National Institute for Health and Care Excellence (NICE)	Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 726
2021	Swiss Federal Office of Public Health (FOPH)	Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis
2021	Institute for Clinical and Economic Review (ICER)	Belimumab and voclosporin for lupus nephritis: effectiveness and value
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Acalabrutinib (pretreated chronic lymphocytic leukaemia) - Addendum to Commission A20-105]
2021	National Institute for Health and Care Excellence (NICE)	Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 727
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guidelines and standards: needs analysis grid for families followed by Integrated Perinatal and Early Childhood Services (SIPPE)]
2021	Institute for Clinical and Economic Review (ICER)	Treatments for anemia in chronic kidney disease: effectiveness and value
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tucatinib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Midostaurin for treating advanced systemic mastocytosis. NICE technology appraisal guidance 728
2021	Swiss Federal Office of Public Health (FOPH)	Medical cannabis for treating various symptoms in Switzerland
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Fall risk assessment in oncology patients
2021	Institute for Clinical and Economic Review (ICER)	Bempedoic acid and inclisiran for patients with heterozygous familial hypercholesterolemia and for secondary prevention of ASCVD: effectiveness and value
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Selpercatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Delaying surgery for patients recovering from COVID-19. A rapid review comissioned by RACS
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Phosphodiesterase type-5 inhibitors for the treatment of secondary Raynaud's phenomenon and digital ulcers
2021	National Institute for Health and Care Excellence (NICE)	Sapropterin for treating hyperphenylalaninaemia in phenylketonuria. NICE technology appraisal guidance 729
2021	Swiss Federal Office of Public Health (FOPH)	Palbociclib (Ibrance®), ribociclib (Kisqali®) and abemaciclib (Verzenios®) for the treatment of hormone receptor (HR)-positive, human epidermal growth factor (HER2)-negative advanced breast cancer
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Effects of masks on the health of schoolchildren
2021	Canary Health Service	[Effectiveness and cost-effectiveness of universal eating disorders prevention in children, preadolescents and adolescents at school]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (oesophageal cancer) - Addendum to Commission A20-121]
2021	National Institute for Health and Care Excellence (NICE)	Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal). NICE technology appraisal guidance 730
2021	Ontario Health	Nonthermal endovenous treatments for varicose veins
2021	Swiss Federal Office of Public Health (FOPH)	Subacromial decompression as a primary/isolated intervention to treat subacromial pain
2021	NIHR Health Technology Assessment programme	Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Selpercatinib (RET mutant medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal). NICE technology appraisal guidance 731
2021	Ontario Health	Prostatic artery embolization for benign prostatic hyperplasia
2021	Swiss Federal Office of Public Health (FOPH)	The treatment of hypercholesterolaemia and mixed/combined hyperlipidaemia with ezetimibe-containing medicines
2021	Belgian Health Care Knowledge Centre (KCE)	Long COVID: Pathophysiology – epidemiology and patient needs
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Selpercatinib (RET fusion-positive thyroid cancer) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal). NICE technology appraisal guidance 732
2021	Ontario Health	Skin substitutes for adults with diabetic foot ulcers and venous leg ulcers
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: creation and characterization of a Québec lung cancer patient cohort using clinical administrative data]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Imlifidase (kidney transplantation) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. NICE technology appraisal guidance 733
2021	Ontario Health	Repetitive Transcranial Magnetic Stimulation for People With Treatment-Resistant Depression
2021	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Screening for common mental disorders during pregnancy and for traumatic experiences after delivery]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: consent process and disposition options for embryos preserved following in vitro fertilization]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fedratinib (myelofibrosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Secukinumab for treating moderate to severe plaque psoriasis in children and young people. NICE technology appraisal guidance 734
2021	Ontario Health	Pigmented lesion assay for suspected melanoma lesions
2021	Norwegian Institute of Public Health (NIPH)	[Liposuction (lipectomy) for the treatment of fat accumulation caused by chronic lymphoedema]
2021	Austrian Institute for Health Technology Assessment (AIHTA)	[Nivolumab in malignant melanoma: contrasting the evidence from pivotal trials with real world evidence (RWE)]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Percutaneously implanted interatrial shunt for the treatment of heart failure - Addendum to commission H20-06]
2021	National Institute for Health and Care Excellence (NICE)	Tofacitinib for treating juvenile idiopathic arthritis. NICE technology appraisal guidance 735
2021	Ontario Health	Proton Beam Therapy for Cancer in Children and Adults: A Health Technology Assessment
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: submission of surgical specimens to the anatomic pathology laboratory - relevance and indications - orthopedic surgery and neurosurgery]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Coronary lithoplasty for coronary heart disease - Addendum to commission H20-07]
2021	National Institute for Health and Care Excellence (NICE)	Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy. NICE technology appraisal guidance 736
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: use of the SpaceOAR hydrogel rectal spacer during prostate radiotherapy]
2021	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: mandatory vaccination
2021	Health Technology Wales (HTW)	Handheld single lead electrocardiogram devices to detect atrial fibrillation in older adults and those with intermittent episodes
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Endovascular implantation of a stent graft with a valve component for tricuspid regurgitation - Addendum to commission H20-08]
2021	National Institute for Health and Care Excellence (NICE)	Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer. NICE technology appraisal guidance 737
2021	Ontario Health	Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure
2021	Health Technology Wales (HTW)	Point-of-care ultrasound to diagnose gallstone disease
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Upadacitinib (psoriatic arthritis) - Addendum to Commission A21-15]
2021	National Institute for Health and Care Excellence (NICE)	Berotralstat for preventing recurrent attacks of hereditary angioedema. NICE technology appraisal guidance 738
2021	Ontario Health	Vaginal pessaries for pelvic organ prolapse and stress urinary incontinence
2021	Scottish Medicines Consortium (SMC)	Secukinumab for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Carfilzomib (multiple myeloma) - Addendum to Commission A21-08]
2021	National Institute for Health and Care Excellence (NICE)	Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable. NICE technology appraisal guidance 739
2021	Scottish Medicines Consortium (SMC)	Brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL)
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Levofloxacin/dexamethasone (inflammation and infection associated with cataract surgery) - Addendum to Commission A21-12]
2021	National Institute for Health and Care Excellence (NICE)	Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer. NICE technology appraisal guidance 740
2021	Scottish Medicines Consortium (SMC)	Melatonin (Slenyto) for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
2021	Health Technology Wales (HTW)	Natriuretic peptides to rule-in and rule-out a diagnosis of acute heart failure in adults in the emergency department setting
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for updating the DMP "Asthma"]
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	National spending and uptake of mobile radiology services in aged care facilities: an opportunity to improve access remains
2021	National Institute for Health and Care Excellence (NICE)	Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 741
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Ambulatory antibiotic prophylaxis for skin procedures
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Selpercatinib for treating advanced thyroid cancer with RET alterations. NICE technology appraisal guidance 742
2020	Technology Assessment at SickKids (TASK)	Microcosting of whole genome sequencing (WGS) of trios in heterogeneous pediatric cardiac population
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: prophylactic use of hydroxychloroquine (HCQ)
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Biomarker-based tests to support the decision for or against adjuvant systemic chemotherapy in primary breast cancer - state of knowledge]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: treatment with hydroxychloroquine (HCQ)
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Gilteritinib (AML) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: infectivity of patients who have recovered from disease